Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Filgotinib - Galapagos/Gilead Sciences

Drug Profile

Filgotinib - Galapagos/Gilead Sciences

Alternative Names: Filgotinib hydrochloride; Filgotinib Maleate; G-146034; G-146034-101; GLPG-0634; GS-6034; Jyseleca

Latest Information Update: 20 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Galapagos NV
  • Developer Eisai Co Ltd; Galapagos NV; Gilead Sciences
  • Class 2 ring heterocyclic compounds; Amides; Anti-inflammatories; Antipsoriatics; Antirheumatics; Cyclopropanes; Pyridines; Skin disorder therapies; Small molecules; Thiamorpholines; Triazoles; Urologics
  • Mechanism of Action Janus kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Rheumatoid arthritis; Ulcerative colitis
  • Phase III Axial spondyloarthritis
  • Phase I Juvenile rheumatoid arthritis
  • Discontinued Ankylosing spondylitis; Crohn's disease; Cutaneous lupus erythematosus; Lupus nephritis; Non-radiographic axial spondyloarthritis; Psoriatic arthritis; Sjogren's syndrome; Uveitis

Most Recent Events

  • 07 Mar 2024 Phase-I clinical trials in Juvenile rheumatoid arthritis (In children, In adolescents, Treatment-experienced) in France, Germany (PO) (NCT06222034) (EudraCT2023-505844-21-00)
  • 31 Jan 2024 Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
  • 31 Jan 2024 Galapagos NV plans a phase I trial for Juvenile rheumatoid arthritis (In children, Treatment-experienced) in United Kingdom (PO) (NCT06222034)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top